Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) ...
Reports $13.2 million in Revenue in the Fourth Quarter, $45.2 million for Full-Year of 2025, Representing increases of 60% and 53%, respectively, Versus the Prior Year PeriodsReaffirms 2026 Revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results